$ 123.5
Key Takeaways
Risk factor
Good trading liquidity
Profitability factor
Greatly overvalued vs peers
About
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB
Target Price
The average target price of RGEN is 174 and suggests 40% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
